TruPlan Computed Tomography (CT) Imaging Software vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

TruPlan Computed Tomography (CT) Imaging Software

by Circle Cardiovascular Imaging

EchoNext

by Pathway Labs

AI Verdict

TruPlan and EchoNext are adjacent tools in the cardiology AI space. TruPlan focuses on advanced visualization and planning for Left Atrial Appendage Closure (LAAC) procedures using CT imaging, offering detailed pre- and post-procedural support. EchoNext, conversely, analyzes standard ECGs to detect hidden structural heart disease, providing a non-invasive diagnostic aid for a broader range of cardiac conditions. While both serve cardiology, their distinct data inputs and procedural applications make them complementary rather than direct competitors.

Choose TruPlan Computed Tomography (CT) Imaging Software if…

Choose TruPlan Computed Tomography (CT) Imaging Software if your cardiology practice or hospital specializes in Left Atrial Appendage Closure (LAAC) procedures and requires comprehensive pre-procedural planning and post-procedural follow-up. This AI-powered tool excels at detailed 3D anatomical assessment, automated LAA landing zone definition, and TEE/fluoro simulations, which can lead to reduced procedural times and improved outcomes for LAAC device implantations.

View TruPlan Computed Tomography (CT) Imaging Software →

Choose EchoNext if…

Choose EchoNext if your clinical setting, from major hospitals to community practices, aims to broadly screen for hidden structural heart disease using standard ECGs. This FDA-cleared AI tool can detect indicators for conditions like heart failure, valve disease, and pulmonary hypertension, enabling earlier identification and intervention before symptoms become apparent.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	TruPlan Computed Tomography (CT) Imaging Software	EchoNext
Pricing	Contact for pricing.	Starts at $600/month
Deployment	On-premise (integrates with PACS/VNA, AI algorithms processed within user infrastructure).	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	Yes AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

TruPlan Computed Tomography (CT) Imaging Software

TruPlan emphasizes an intuitive and easy-to-use interface with simplified workflows, including features like drag-and-drop and MacOS compatibility, which generally contribute to a better user experience. EchoNext's deployment through the OpenEvidence platform suggests integration, but specific usability features are not detailed.

Clinical Value

EchoNext

EchoNext has demonstrated superior accuracy in detecting structural heart disease from ECGs compared to cardiologists, even those assisted by AI, and has been credited with guiding care that led to a heart transplant. TruPlan aids in pre- and post-procedural planning for LAAC, improving procedural efficiency and success rates, but EchoNext's broader diagnostic capability and proven impact on patient outcomes give it an edge.

Pricing & Value

EchoNext

EchoNext offers transparent tiered pricing starting at $600/month, providing clear cost expectations for potential users. TruPlan requires contacting for pricing, which can be a barrier to initial assessment of value. EchoNext's ability to screen for structural heart disease using a low-cost, routine ECG also suggests significant cost-effectiveness.

Enterprise Readiness

EchoNext

EchoNext is available through the OpenEvidence clinical decision support platform, which is used by 650,000 U.S. physicians, indicating a strong existing infrastructure for broad deployment and integration within healthcare systems. TruPlan offers on-premise deployment and PACS/VNA integration, but EchoNext's wider platform availability suggests greater enterprise readiness.

Innovation

EchoNext

EchoNext is highlighted as the world's first FDA-approved AI detection tool to analyze ECGs for hidden structural heart disease, representing a significant breakthrough in early detection. TruPlan utilizes machine learning for automated LAA landing zone definition and 3D anatomical assessment, which are innovative, but EchoNext's novel application of AI to a widely available, inexpensive test for broad disease screening is a more impactful innovation.

Support & Docs

Tie

Both tools are FDA-cleared medical devices, implying a certain standard of documentation and support. TruPlan provides an installation guide, user manual, release notes, and DICOM Conformance Statement. While EchoNext's documentation isn't explicitly detailed, its collaboration with OpenEvidence and ongoing clinical validation suggest robust support. Without more specific information on EchoNext's documentation and support offerings, it's difficult to definitively pick a winner.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	TruPlan Computed Tomography (CT) Imaging Software	EchoNext
Name	TruPlan Computed Tomography (CT) Imaging Software	EchoNext
Company	Circle Cardiovascular Imaging	Pathway Labs
Description	AI-powered medical device for comprehensive visualization and planning of Left Atrial Appendage Closure (LAAC) procedures.	FDA-cleared AI tool that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Categories	Cardiology AI, Radiology & Imaging AI, Surgical AI	Cardiology AI, Clinical Decision Support & Reference, Lab & Diagnostics
Key Features	Comprehensive visualization for Left Atrial Appendage Closure (LAAC), Pre-procedural planning for LAAC procedures, Post-procedural follow-up for LAAC procedures, Automated LAA landing zone definition using machine learning, 3D anatomical assessment, including segmentation and sculpting, Endoluminal view to LAA and Left Atrium (LA), TEE (Transesophageal Echocardiography) simulation with prepopulated views and simultaneous fluoro/3D, Fluoro Workflow Enhancements	AI-powered ECG analysis, Detection of hidden structural heart disease, Identifies heart failure risk, Screens for valve disease, Detects pulmonary hypertension indicators, Utilizes standard 12-lead ECGs, FDA-cleared technology, Non-invasive diagnostic support

Videos

Demos, reviews, and walkthroughs featuring TruPlan Computed Tomography (CT) Imaging Software and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing cardiology workflows and EHR systems?

TruPlan is an on-premise solution that integrates with PACS/VNA systems, focusing on pre- and post-procedural planning for Left Atrial Appendage Closure (LAAC) using CT imaging. EchoNext is available through the OpenEvidence clinical decision support platform, analyzing standard ECGs to detect structural heart disease and potentially streamlining triage for advanced imaging.

What is the accuracy and sensitivity of each tool in detecting cardiac conditions?

EchoNext has demonstrated high accuracy in detecting structural heart disease (SHD), with an AUROC of 85.2% in internal tests and 78-80% in external validation. In studies, EchoNext alone achieved 77% accuracy in identifying SHD from ECGs, outperforming cardiologists who achieved 64% accuracy without AI assistance. TruPlan provides visualization and measurement tools for LAAC procedures based on CT images, aiding in device sizing and placement, but it is not intended for diagnosis and acts as an adjunct to typical clinical workflow.

For which specific cardiac specialties and clinical contexts are these tools best suited?

TruPlan is specifically designed for cardiologists and radiologists involved in Left Atrial Appendage Closure (LAAC) procedures, offering comprehensive visualization and planning based on CT imaging. EchoNext is a broader screening tool for cardiologists, family medicine, hospital medicine, and internal medicine, as it analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.

What is the typical learning curve for physicians to become proficient with each tool?

TruPlan is described as easy to use with intuitive controls for quick pre-planning and a simplified LAA workflow, including fluoro workflow enhancements and auto TEE/ICE views. While not explicitly stated for EchoNext, its integration with the OpenEvidence platform suggests a focus on accessibility for a broad range of physicians, from major hospitals to community practices.

What kind of customer support and resources are available for each tool?

For TruPlan, Boston Scientific's WATCHMAN clinical specialists provide support for both the software and the LAAC procedures. For EchoNext, while not detailed, its availability through the OpenEvidence platform implies support from OpenEvidence, which aims to make high-impact technology accessible to physicians without long procurement cycles.

Are there customer references or case studies available to demonstrate real-world value?

TruPlan has a case study from The Valley Health Hospital, a non-academic regional medical center, which reported a 33% decrease in procedural time and a 50% increase in capacity and procedures per day after using TruPlan. EchoNext has been the subject of multiple studies published in Nature and Nature Medicine, demonstrating its efficacy and outperforming cardiologists in detecting structural heart disease.

What audit-trail features are included to ensure accountability and track usage?

The provided information does not explicitly detail specific audit-trail features for either TruPlan or EchoNext. However, as medical devices, both would be expected to adhere to regulatory requirements regarding data integrity and accountability.